Trial Profile
A retrospective study of nivolumab and pembrolizumab in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.